It does not receive public funding
Editor in chief:
CLARA MOSCHINI

Facebook Twitter Youtube Instagram LinkedIn

Capital increase of $130 million for Huma digital health

Hat is the only Italian private equity investor

Leaps by Bayer and Hitachi Ventures led the capital increase, which sees, alongside existing shareholders, new strategic and financial investors such as Samsung Next, Sony Innovation Fund by Igv, Unilever Ventures.

Huma Therapeutics Limited, an international healthcare technology company that combines predictive care and machine learning, has announced the completion of a capital increase of $ 130 million (approximately € 107 million). There is the option to approve a further capital increase of $ 70 million (approximately € 58 million) to be exercised in the future, which would bring the total capital raised to more than $ 200 million (approximately € 165 million). Huma was recently named by the Financial Times as the fastest growing healthcare company in Europe. The only Italian private equity operator chosen as a strategic and financial partner in the investment is Hat, which enters with its Hat Technology & Innovation fund to support Huma's growth on the domestic market.

Leaps by Bayer and Hitachi Ventures led the capital increase, which sees, alongside existing shareholders, new strategic and financial investors such as Samsung Next, Sony Innovation Fund by Igv, Unilever Ventures, in addition to the Italian Hat fund, as well as Nikesh Arora (former president of SoftBank) and Michael Diekmann (president of Allianz). The new investment will be destined for the expansion of Huma's digital platform at an international level and, in particular, in the United States, in Asia, in Europam and therefore also in Italy, and in the Middle East. The resources will also allow the technological and commercial development of the platform, with the aim of bringing proactive and predictive care on a global scale and feeding "hospitals at home", in digital form, supporting pharmaceutical companies and scientific research. in the largest decentralized clinical trials ever performed. Hat, led by Ignazio Castiglioni and chaired by Nino Attanasio, is one of the leading independent Italian players active in the alternative investment market, with an important specialization in tech and innovation.

hef - 18910

EFA News - European Food Agency
Similar